Condition: Hypercholesterolemia · Dyslipidemias · Primary Hypercholesterolemia · Sponsor: Hasten Biopharmaceutical Co., Ltd.
This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W \[≤31 days\]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high/high risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.
This description comes directly from the study's public registry record.
Yong Huo · +86 13901333060 · huoyong@263.net.cn
Always discuss trial participation with your own doctor first.
| Beijing Anzhen Hospital of Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Luhe Hospital, Capital Medical Univeristy | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Tsinghua Changgeng Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fuwai Hospital, CAMS & PUMC | Beijing, Beijing Municipality, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Shijiazhuang People's Hospital | Shijiazhuang, Hebei, China | Recruiting |
| Daqingshi People's Hospital | Daqing, Heilingjiang, China | Recruiting |
| The 2nd Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| The Third Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| Nanchang People's Hospital | Nanchang, Jiangxi, China | Recruiting |
| Binzhou Medical University Hospital | Binzhou, Shandong, China | Recruiting |
| Heze Municipal Hospital | Heze, Shandong, China | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06568471